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ABSTRACT Mucus hyper-secretion is a hallmark feature of asthma and other muco-obstructive airway diseases. The mucin proteins
MUC5AC and MUC5B are the major glycoprotein components of mucus and have critical roles in airway defense. Despite the
biomedical importance of these two proteins, the loci that regulate them in the context of natural genetic variation have not been
studied. To identify genes that underlie variation in airway mucin levels, we performed genetic analyses in founder strains and incipient
lines of the Collaborative Cross (CC) in a house dust mite mouse model of asthma. CC founder strains exhibited significant differences
in MUC5AC and MUC5B, providing evidence of heritability. Analysis of gene and protein expression ofMuc5ac andMuc5b in incipient
CC lines (n = 154) suggested that post-transcriptional events were important regulators of mucin protein content in the airways.
Quantitative trait locus (QTL) mapping identified distinct, trans protein QTL for MUC5AC (chromosome 13) and MUC5B (chromosome 2).
These two QTL explained 18 and 20% of phenotypic variance, respectively. Examination of the MUC5B QTL allele effects and
subsequent phylogenetic analysis allowed us to narrow the MUC5B QTL and identify Bpifb1 as a candidate gene. Bpifb1 mRNA
and protein expression were upregulated in parallel to MUC5B after allergen challenge, and Bpifb1 knockout mice exhibited higher
MUC5B expression. Thus, BPIFB1 is a novel regulator of MUC5B.
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EXCESSIVE mucus in the airways is a hallmark featureof muco-obstructive airway diseases including asthma,
chronic obstructive pulmonary disease (COPD), and cystic
fibrosis (CF) (Fahy and Dickey 2010). MUC5AC and MUC5B
are the primary secreted mucins in the airways (Evans et al.
2009) and alterations in the levels and/or post-translational
modifications of each mucin, as well as the ratio between the
two, are associated with different airway diseases (Kirkham
et al. 2002; Fahy and Dickey 2010). MUC5AC is increased at
the mRNA and protein levels in the airways of asthmatics
(Ordoñez et al. 2001) and plays an important role in airway
narrowing and hyper-responsiveness (Evans et al. 2015).
MUC5B is significantly elevated in COPD and CF (Fahy and
Dickey 2010), as well as idiopathic pulmonary fibrosis (IPF)
(Seibold et al. 2011), and is the primary mucin in plugs re-
moved from the lungs after fatal status asthmaticus (Sheehan
et al. 1995; Groneberg et al. 2002). In addition to associations
with disease, MUC5B regulates features of lung homeostasis,
such as mucociliary clearance, suggesting it has a critical role
in lung defense to pathogens (Roy et al. 2013).
While there has been a great deal of research on the
biochemical pathways that regulate mucin genes and corre-
sponding proteins (Rose and Voynow 2006; Davis and Dickey
2008; Thai et al. 2008), the genetic architecture of mucus
phenotypes in both humans and animal models is not well
characterized. Previous studies provided evidence that the
chronic mucus hyper-secretion phenotype in COPD (also
known as chronic bronchitis) has a familial component
(Viegi et al. 1994; Silverman et al. 1998), and results from
a twin study indicated that 40% of variation in the chronic
mucus hyper-secretion phenotype is attributable to genetic
variation (Hallberg et al. 2008). Genome-wide association
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studies have identified two SNPs (rs6577641 in SATB1 and
rs34391416 near the genes EFCAB4A, CHID1, and AP2A2)
associated with chronic mucus hyper-secretion in the context
of COPD (Dijkstra et al. 2014; Lee et al. 2014), but these loci
do not explain a large fraction of the estimated heritability.
This could in part be due to the need to rely on survey data to
ascertain phenotype status in these studies, which dichoto-
mizes the quantitative nature of muco-obstructive pheno-
types and is subject to recall bias, resulting in reduced
power to detect significant associations.
Given the importance of MUC5AC and MUC5B in muco-
obstructive airway diseases, we sought to identify key regula-
tors of these secretedmucins using an unbiased, genome-wide
search. To accomplish this goal, we utilized incipient lines of
the Collaborative Cross (CC). The CC is composed of a panel
of recombinant inbred mouse lines derived from eight-way
crosses using five classical inbred strains (C57BL/6J, 129S1/
SvImJ, A/J, NOD/ShiLtJ, and NZO/H1LtJ) and three wild-
derived inbred strains (WSB/EiJ, PWK/PhJ, and CAST/EiJ)
(Collaborative Cross Consortium 2012). Studies with incipient
and established CC lines have identified quantitative trait loci
for numerous traits of biomedical interest (Aylor et al. 2011;
Kelada et al. 2012, 2014; Rutledge et al. 2014; Gralinski et al.
2015;Mosedale et al. 2017; Venkatratnam et al. 2017).Within
this framework, we applied a house dust mite (HDM) model
(Kelada et al. 2011) to elicit MUC5AC and MUC5B expression
and secretion in mouse airways. We used quantitative protein
measurements of secretedmucins, QTLmapping, gene expres-
sion, and genome sequence data to identify candidate regula-
tors of these secreted mucins. Further, we interrogated the
relationship between MUC5B and the candidate regulator
Bpifb1 with gene and protein expression data, followed by
the use of a knockout strain to validate BPIFB1 as a novel
regulator of MUC5B in the airways.
Materials and Methods
Mice
We obtained 154male pre-CCmice (ages 10–14 weeks) from
Oak Ridge National Laboratory (Chesler et al. 2008). Each
mouse was from an independent CC line that had undergone
5–14 generations of inbreeding. We also obtained male mice
of each of the eight CC founder strains from The Jackson
Laboratory (n=3–4/strainwere phenotyped, plus additional
C57BL/6J mice). All mice were singly housed, with alpha-dri
bedding, under normal 12-hr light/dark cycles. All experi-
ments conducted with mice in this study were compliant with
an Institutional Animal Care and Use Committee protocol at
an animal facility approved and accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care
International.
To generate Bpifb1 KOmice, sperm from hemizygousmale
Bpifb1 mice was obtained from the Knockout Mouse Project
(KOMP) (www.komp.org). These mice were created from
embryonic stem cell clone EPD0704_3_A09 obtained from
the KOMP Repository and generated by the Wellcome Trust
Sanger Institute. Methods used on the targeted alleles have
been published (Skarnes et al. 2011). In this work, the Tm1a
allele was used without subsequent modification or removal
of cassette elements. Sperm was used to fertilize eggs from
C57BL/6NJ mice, and heterozygous offspring were mated to
generate a colony of mice used for the experiment.
Mice were genotyped using a single PCR reaction containing
two different forward primers [wild-type (WT) allele primer:
59-GAAGAGGGAAGGTCAGGAGAAAGGG-39 and knockout
(CSD-neoF) allele primer 59-GGGATCTCATGCTGGAGTTCT
TCG-39] and one common reverse primer (59-TAAGGTCC
TTTGGTCAACGGTTTGC-39). PCR products were analyzed
by gel electrophoresis, with the WT allele producing a 535-bp
product and the knockout allele producing a 646-bp product.
By and large, matings of heterozygous mice produced
Mendelian ratios of offspring. However, in the third genera-
tion we observed transmission ratio distortion with a deple-
tion of homozygous mutant pups (four born, nine expected),
suggesting that either loss of Bpifb1 has some effect on geno-
type ratios that is incompletely penetrant or that an addi-
tional mutation on the strain background contributed to
non-Mendelian ratios. This effect was not observed in three
subsequent generations.
Homozygous WT and knockout littermates (males and
females) were used in experiments in which mice were either
used at baseline (i.e., naïve, no allergen exposure) or sensi-
tized twice (i.p.) with 10 mg of Der p 1 and challenged with
PBS or 50 mg of Der p 1. Within each genotype, mice were
randomized to treatment groups.
Phenotyping protocol
We employed an HDM model of allergic airway disease that
produces hallmark asthma phenotypes including Th2-biased
airway inflammation, elevated serum IgE, mucous cell meta-
plasia, and airway hyper-responsiveness in a strain-dependent
fashion (Kelada et al. 2011). Results for inflammatory cell
recruitment [eosinophils (Kelada et al. 2014) and neutrophils
(Rutledge et al. 2014)], responsiveness to methacholine
(Kelada 2016), and lung gene expression (eQTL) (Kelada
et al. 2014) have been previously published. At the start of
our study, mice were phenotyped by whole body plethysmog-
raphy for baseline responsiveness to methacholine (on days
1 and 8). The mice were then sensitized with 10 mg (in
100 ml) of the immunodominant allergen from the Dermato-
phagoides pteronyssinus species of HDM, Der p 1 (Cat. No.
LTN-DP1-1; Indoor Biotechnology), administered by intra-
peritoneal injection on days 11 and 18 of the protocol. On
day 25, mice were challenged with 50 mg of Der p 1 (in
100 ml), administered by oro-pharyngeal aspiration. Mice
were phenotyped for responsiveness to methacholine again
by whole body plethysmography on day 28. Immediately
following this measurement, mice were killed by an overdose
of pentobarbitol, followed by collection of blood, whole lung
lavage fluid, and lung tissue. Lung lavage was performed
using two successive volumes of 0.5 and 1.0 ml PBS. The first
fraction of lavage fluid was spun down (500 g for 10 min) to
separate out cells and the supernatant was retained for anal-
ysis of mucins by agarose gel electrophoresis followed by
immunoblotting.
Agarose gel electrophoresis and immunoblotting
We used a previously established method (Kirkham et al.
2002) involving agarose gel electrophoresis following by im-
munoblotting to detect MUC5AC and MUC5B in bronchoal-
veolar lavage fluid (BALF). Briefly, the addition of urea
powder (40 mg/0.1 ml) to BALF produced a 6 M urea BALF,
which was reduced with 10 mM dithiothreitol for 90 min and
alkylated with 25 mM iodoacetamide to obtain constituent
mucin monomer subunits. Equal volumes of reduced samples
(40ml) were run on 1% agarose gel. Gels were vacuum-blotted
onto nitrocellulose membranes, blocked with Odyssey block-
ing buffer (LI-COR Biosciences), and probed with a rabbit
polyclonal antibody (Ab) raised against murine MUC5AC or
MUC5B (Ehre et al. 2012) [UNC294 and UNC222, respec-
tively, generously provided by Dr. Camille Ehre (UNC)]. Us-
ing sequence data (Keane et al. 2011), we determined that
there were nomissense variants encoded inMuc5ac orMuc5b
at the epitopes recognized by these antibodies, thus each
antibody-based measurement should have been unbiased
with respect to strain. The secondary Ab was Alexa Fluor
680 goat anti-rabbit IgG, diluted 1/15,000 in Odyssey block-
ing buffer. Detection and analysis of specific signals were
performed using the Odyssey CLx infrared imaging system
(LI-COR Biosciences). For quantification, the integrated in-
tensity of the major high-molecular-weight bands in each
lane was measured by defining a rectangular region of in-
terest (ROI) encompassing these bands in the sample with
the strongest signal and using this ROI for all lanes (as shown
in Supplemental Material, Figure S1, Odyssey software ver-
sion 3.0 or ImageStudio version 1.0.11). The median inten-
sity of three pixels on the right and the left of the defined ROI
was used to define the background, which was subtracted
from the integrated intensity value. Owing to the large num-
ber of pre-CC samples, they had to be run on five different
gels. To normalize the integrated intensity values for transfer
efficiency and antibody binding, the same volume of two
different positive control samples (BALF from C57BL/6N
mice treated with IL-13) was loaded on each row of every
gel (as illustrated in Figure S1), and their integrated intensity
values were used to normalize the values for the pre-CC sam-
ples. BALF fromMuc5ac KO andMuc5b KOmice were used as
controls to confirm antibody specificity as reported in
Livraghi-Butrico et al. (2017). Phenotype data for CC founder
strains and pre-CC mice are given in Table S1 and Table S2,
respectively.
For statistical analyses of pre-CC mice, MUC5AC and
MUC5B intensity values were natural log-transformed. For
MUC5AC, we observed a spike in the distribution at the low
end of the range, suggesting that these values were near
the limit of detection, and we removed these data points
(n = 10 mice) from further analysis.
Heritability estimates
Analysis of variance was used to test whether phenotypes
varied amongCC founder strains. From theseANOVAmodels,
we estimated broad-sense heritability (H2) by calculating the
interclass correlation (r1) and the coefficient of genetic de-
termination (g2) (Festing 1979):
r1 ¼ ðMSB-MSWÞ=ðMSBþ ðn-1ÞMSWÞ;
g2 ¼ ðMSB-MSWÞ=ðMSBþ ð2n-1ÞMSWÞ;
whereMSBandMSWarethemeansquaresbetweenandwithin,
respectively, from the eight-wayANOVAmodel describedabove
and n is the number of mice per strain (n = 3–4/strain).
Genotyping, quantitative trait locus (QTL) mapping,
and phylogeny
Wegenotyped eachmouse at theUniversity of North Carolina
at Chapel Hill using one of two Affymetrix SNP arrays (A or B)
that were produced during the development of the Mouse
Diversity array (Yang et al. 2009), resulting in 27,059 map-
ping intervals, as described in a previous study (Rutledge
et al. 2014). These genotyping arrays were annotated to
NCBI Build 36 of the mouse genome, but we mapped QTL
boundaries to Build 37 positions and we report Build 37 po-
sitions in our results. We used BAGPIPE (Valdar et al. 2009)
to fit a regression model and report LOD scores for QTL map-
ping of mucin protein levels. ForMUC5AC, QTLmapping was
carried out using the data set after removal of values below
the apparent threshold of detection. Inclusion of values be-
low the threshold resulted in no significant QTL. Significance
thresholds were determined by permutation (n = 10,000).
We used the 1.5 LOD drop method to approximate confi-
dence interval for QTL (Dupuis and Siegmund 1999). The
proportion of variance explained for each QTL was estimated
by regression of phenotypes on genotype for the peak locus
for each QTL. Allele effects plots were used to identify puta-
tive functional haplotype groupings using a previously estab-
lished method (Kelada et al. 2012). Post hoc statistical tests
of these haplotypes were conducted using Tukey’s honestly
significant difference test. To build a phylogenetic tree relat-
ing the eight CC founder strains at the Chr 2 QTL, we gener-
ated sequence alignments using sequence data (http://www.
sanger.ac.uk/sanger/Mouse_SnpViewer/rel-1211) (Keane
et al. 2011) and then generated a maximum likelihood tree
using RAxML version 7.2.9 (Stamatakis 2006). One hundred
bootstrap samples were used to assess the support for each
tree branch. Please see File S1 for code used to run RAxML.
Candidate gene identification
To identify candidate genes for the MUC5B QTL on Chr 2, we
applied a weight of evidence approach based on a series of
criteria. This included the following criteria:
1. Evidence that the gene is expressed in airway epithelia,
based on expression data from a previous study (GSE34764)
(Doherty et al. 2012). Specifically, we used samples from the
control group (PBS, n= 3) of GSE34764 to characterize the
distribution of gene expression and then categorized genes in
thebottomfifth percentile as not expressedwhile genes above
or equal to the fifth percentile were considered expressed.
2. Evidence that the gene is differentially expressed in whole
lung RNA samples as a function of allergen treatment, based
on a previous studywe conducted (GSE19223) (Kelada et al.
2011). For this criterion, we conducted an analysis of differ-
ential expression using Partek software (version 6.6) and
used nominal P-values ,0.05 and fold change .1.5.
3. Evidence that the gene is differentially expressed in nor-
mal lung tissue as a function of Chr 2 founder haplotype,
which was assessed using two independent gene expres-
sion data sets involving strains from different subspecies
[A/J (musculus haplotype) and C57BL/6J (domesticus
haplotype) in GSE30015 and WSB/EiJ (domesticus haplo-
type) and PWK/PhJ (musculus haplotype) in GSE44555]
(Crowley et al. 2015). This analysis was conducted using
R (version 3.1.2) using the MAANOVA package after
masking for probesets that contain variants frommusculus
haplotypes. For this criterion, we did not specify a fold
change cutoff, only a nominal statistical significance
threshold of ,0.05. However, we did specify that the di-
rection of the gene expression difference (either higher or
lower) be consistent across the two studies.
4. Unique sharing of nonsynonymous variants among the Chr
2musculus haplotypes. We used sequence data (Keane et al.
2011) and a corresponding web query tool (http://www.
sanger.ac.uk/sanger/Mouse_SnpViewer/rel-1211) to iden-
tify nonsynonymous variants that are shared by A/J, NOD/
ShiLtJ, and PWK/PhJ strains and not present in other CC
founder strains.
5. Prior evidence of biological relevance. We conducted lit-
erature searches in PubMed and used the Mouse Genome
Informatics website to find previously published evidence
that a particular gene may be relevant to allergic airway
inflammation and/or mucus production/secretion.
Gene expression by qRT-PCR
RNA from the right lung middle lobe was isolated using the
RNEasy Kit (Qiagen, Valencia, CA) and reverse transcribed
using theHighCapacityRNAto cDNAkit (AppliedBiosystems,
Foster City, CA) according to manufacturers’ protocols. TaqMan
assays for Muc5b and Bpifb1 were custom designed to avoid
genetic variants at these loci in the CC founder strain genomes.
Assays were validated for efficient amplification using serial
dilutions of template. Primer and probe pairs are as follows:
Muc5b F: 59-AAGGTGTATGTACCAACTGG-39, R: 59-TGTAC
TATCCTGGGTCCTC-39, Probe: 59-TGTGACCTCTCCTGTC
CACCCAC-39; Bpifb1 F: 59-CACAAGCTCTCCTTCGTG-39, R:
59-TACATGTCATCAAAGGCCTG-39, Probe: 59-TGAATCTCCTG
GTGCCAGCCCTG-39. DCt values were calculated by normaliz-
ing to Rps20 (Mm02342828_g1, Applied Biosystems). A two-sided
or one-sided Student’s t-test was used to analyze the data as
noted, and a significant change was defined as a = 0.05.
Histology and immunohistochemistry
Formalin-fixed left lung lobes were cut in cross-section start-
ing at the hilum and 2 mm apart along the main stem
bronchus, yielding three slices/lung (level 1, 2, and 3 from
rostral to caudal). All three slices were embedded in paraffin,
and 5-mm-thick sections were cut and stained with AB-PAS.
Immunohistochemistry forMUC5B and BPIFB1was performed
as previously described (Livraghi-Butrico et al. 2017). Briefly,
sections were incubated for 1 hr with FC Block (BD Pharmigen)
at 1:200 in 5% normal goat serum (NGS) (JacksonImmuno)
in phosphate buffered saline with 0.1% Tween-20 and for
3 hr with 1:1000 MUC5B (H-300, Santa Cruz Biotech) or
1:200 BPIFB1 (HP8044, Hycult Biotech) primary antibodies
in 5%NGS. Rabbit IgG (JacksonImmuno)was used as isotype
control for both antibodies. Goat anti-rabbit biotinylated sec-
ondary antibody (JacksonImmuno) was applied on all sec-
tions at 1:200 in 5% NGS for 30 min. The VECTSTAIN Elite
ABC R.T.U and Immpact NovaRed horseradish peroxidase
detection systems (Vector Laboratories, Burlingame, CA) were
used according to the manufacturer’s protocols. Slides were
counterstained with Mayer’s hematoxylin before dehydration
and mounting with DPX (Sigma Aldrich). Slides were imaged
on an Olympus BX60F5 microscope with CellSens Standard
software (Olympus Life Sciences version 1.13).
Morphometric analysis
Total airway or luminal histological staining was quantified
morphometrically on level 1 (the level most affected bymucous
cell metaplasia andmucus accumulation) by investigators blind
to treatment and genotype. Total, intraepithelial (stored), and
luminal AB-PASpositive andMUC5BorBPIFB1-positive volume
densities (Vs) were quantified using 103 or 203magnification
micrographs as previously described (Harkema et al. 1987).
Meta-analysis of gene expression data
Eight gene expression data from mouse models of asthma
were identified in NCBI ’s GEO database (GSE1301,
GSE13032, GSE13382, GSE1438, GSE19223, GSE27066,
GSE34764, and GSE6858). In all but one case (GSE1438),
data were downloaded then normalized (using the default
robust multi-array average with quantile normalization
method) using Partek software (version 6.6). Statistical anal-
ysis of differential gene expression was also conducted in
Partek, accounting for strain if .1 strain was included in
the study. For GSE1438, we used NCBI’s GEO2R web-based
software to conduct data analysis because of the custom ar-
rays used in that experiment. Meta-analysis of gene expres-
sion data from NCBI’s GEO repository was conducted using
Fisher’s combined probability test.
Data availability
Supplemental Material is provided in File S1, a zip file con-
taining perl scripts used in QTL mapping and code use for
phylogenetic analysis. Phenotype data are provided in Table
S1 and Table S2. Genotype calls for pre-CCmice are available at
http://www.genetics.org/content/198/2/735.supplemental.
Results
To identify regulators of secretedMUC5AC andMUC5B in the
airway, we applied an HDM model of asthma (Kelada et al.
2011) involving the immunodominant antigen Der p 1. In
preliminary experiments using C57BL/6Jmice, we quantified
secreted MUC5AC and MUC5B levels in BALF after Der p 1 al-
lergen sensitization and challenge using agarose gel electro-
phoresis followed by immunoblotting. These experiments
revealed that the vast majority of MUC5AC andMUC5B were
contained in the soluble fraction of BALF and that allergen
treatment increased MUC5AC 10-fold and MUC5B 6-fold
(Figure S2). We then phenotyped CC founder strains for
MUC5AC and MUC5B BALF levels after allergen sensitization
and challenge, and we included a subset of A/J mice that were
sensitized but challenged only with PBS (vehicle). As shown in
Figure 1, levels of MUC5AC and MUC5B in BALF varied signif-
icantly by strain. For both mucins, the effect of strain was
greater than the effect of treatment alone in the A/J strain.
Estimates of broad-sense heritability for MUC5AC among aller-
gen sensitized and challenged mice based on interclass correla-
tions (r1) and the coefficient of genetic determination (g2) were
0.77 and 0.63, respectively. ForMUC5B, the corresponding her-
itability estimates were 0.69 and 0.53. These results indicate
that variation in the levels of both mucins is significantly asso-
ciated with variation in the genome.
We then phenotyped 154 incipient lines of the CC, which
we refer to as “pre-CC”mice. Each pre-CCmouse was derived
from a different CC breeding funnel and contained allelic
contributions from all eight founder strains (Aylor et al. 2011).
Pre-CC mice were treated with Der p 1 allergen and exhibited a
wide range of MUC5AC and MUC5B levels in BALF (Figure S3).
We examined pairwise correlations between MUC5AC and
MUC5B and found a weak but statistically significant and
positive correlation between the two mucin proteins (Figure
S4; r=0.25, P=0.005), where the correlation was strongest
toward the higher ranges of MUC5AC and MUC5B expres-
sion. In contrast, pairwise correlations of Muc5ac and Muc5b
mRNA [assessed using previously generated data (Kelada
et al. 2014)] were quite strong (Figure S4; r = 0.83, P ,
1 3 1024). Interestingly, pairwise correlations between each
mucin mRNA and protein were weak or absent, suggesting
post-transcriptional events that uncouple intracellular mRNA
and secreted protein levels.
To identify the specificgenetic loci that controlmucin levels
in response to allergen sensitization and challenge, we used
the pre-CC phenotype and genotype data tomapQTL for each
mucin protein (Figure 2). For MUC5AC, we identified a QTL
on Chr 13 (Muc5acq1, LOD=7.2, Figure 2A), spanning 71.6–
81.0 Mb, and for MUC5B, we identified a QTL on Chr
2 (Muc5bq1, LOD = 7.9, Figure 2B), spanning 152.5–159.8
Mb. These two QTL explained 18 and 20% of phenotype
variation, respectively. The genes encoding both mucins are
located on Chr 7, indicating these two pQTL act in trans, and
the fact that the two trans-pQTL are different indicates dif-
ferential regulation of each mucin.
We then sought to identify candidate genes for each QTL,
initially using theQTLallele effects patternas away to identify
potentially functionally distinct alleles at each locus and
prioritize genes (Kelada et al. 2012). For Muc5acq1, there
were no obvious differences in phenotype among pre-CC
mice categorized by most probable CC founder haplotype
(Figure S5). As such, we turned to other data to identify
potential candidate genes for Muc5acq1. This locus contains
47 protein-coding genes and 50 noncoding RNAs. Expression
data were available for 45 of the 47 protein-coding genes
(based on GSE51768), and we assessed pairwise correlation
of each gene with BALF MUC5AC. Eight genes were associ-
ated with MUC5AC at a nominal P-value threshold of 0.05
(Table S3). We also asked whether any of these genes had
local eQTL using a previously generated eQTL data set from
the same set of mice (Kelada et al. 2014). Fifteen genes of the
47 had eQTL (Table S3). Finally, we conducted a literature
search to see if any of the 47 genes had potential links to
MUC5AC. In aggregate, no single gene stood out in terms
of pairwise correlation and eQTL; however, evidence for bi-
ological plausibility for four genes (Slc9a3, Nr2f1, Glrx1, and
Spata9) was obtained from the literature search. As such,
these genes may be worthy of additional investigation in re-
lation to MUC5AC.
In contrast to the allele effects for Muc5acq1, the allele
effects forMuc5bq1were striking. We found that alleles from
A/J, NOD/ShiLtJ, and PWK/PhJ were associated with signif-
icantly lower levels of MUC5B (Figure 2C), indicating that
these three alleles share functional similarities that result in
low MUC5B BALF levels. Visualization of founder haplotypes
based on high-density genotyping (Wang et al. 2012) in this
region revealed that these three strains all share a Mus mus-
culus musculus-derived haplotype spanning 152–154 Mb
(Figure S6), indicating intersubspecific introgression (Yang
et al. 2011) of musculus haplotypes into the genomes of the
A/J and NOD/ShiLtJ strains (classical inbred strains of
domesticus origin). Using unbiased sequence data (Keane
et al. 2011), we constructed a phylogenetic tree for this re-
gion and confirmed that these three strains have musculus-
derived alleles that are distinct from all other CC founder
strains (Figure 2D). This result indicates (based on parsi-
mony) that themusculus haplotypes contain a functional var-
iant (or variants) that cause lower MUC5B.
To prioritize candidate genes underlying theMuc5bq1, we
could not rely on gene expression data for genes in this region
because themicroarray platformwe used (Kelada et al. 2014)
was based on C57BL/6J sequence and therefore was biased
against M. m. musculus and castaneus transcripts emanating
from Muc5bq1. We therefore chose to leverage other data
sets to prioritize candidate genes. As described in the meth-
ods, we applied aweight of evidence approach to the gene list
to prioritize genes based on expression in a relevant cell type
(airway epithelia), change in expression in the lung due to
allergen treatment, differences in expression in the lung due
to subspecies origin, the presence of predicted amino acid
variants shared by A/J, NOD/ShiLtJ, and PWK/PhJ founder
strains, and previously published papers documenting a role
for a gene in relevant biological pathways (Figure S7). This
approach identified Bpifb1 as a priority candidate gene be-
cause it met all of the aforementioned criteria.
Bpifb1 is a member of the BPI (bactericidal/permeability-
increasing protein)/LBP (lipopolysaccharide-binding protein)
family of lipid-transfer proteins, and was previously known
as Lplunc1 for long palate lung and nasal epithelia clone
(Bingle et al. 2011). Previous studies in humans documented
expression of BPIFB1 in goblet cells of the respiratory epithe-
lium (Bingle et al. 2010), secretion into the airways (Bingle
et al. 2010; Gao et al. 2015), and upregulation in CF (Bingle
et al. 2012) and COPD (Gao et al. 2015; Titz et al. 2015). In
contrast, BPIFA1 is down-regulated in asthma models (Chu
et al. 2007; Wu et al. 2017).
To begin evaluating a potential role of Bpifb1 in MUC5B
regulation, we examined lung gene expression in pre-CC mice
followed by gene and protein expression in control and allergen-
treated inbred strains. For the pre-CC mice, we performed
qRT-PCRwith gene expression probes designed to avoid genetic
variation in the CC founder genomes.We found thatMuc5b and
Bpifb1 mRNA were strongly and positively correlated among
pre-CC mice (r = 0.75, P , 1 3 1024, Figure S8). This result
prompted us to ask whether Muc5b and Bpifb1 were jointly
upregulated in other mouse models of asthma. As shown in
Table 1, we found that expression of both Muc5b and Bpifb1
were nearly always increased in response to allergens such as
ovalbumin, Alternaria, and HDM across three different in-
bred strains. Meta-analysis confirmed significant differential
expression, with meta-analysis P-values of 1.5 3 10213 and
1.8 3 10210 for Muc5b and Bpifb1, respectively. Thus, this
correlation appears to be generalizable to other mouse mod-
els of asthma. Lastly, we evaluated the correlation between
MUC5B and BPIFB1 in C57BL/6J mice after sensitization
and challenge with allergen or PBS (Figure 3). We found
that the expression of both proteins increased significantly
as a function of allergen (Figure 3B) in a highly correlated
fashion (r = 0.98, P , 0.001, Figure 3C).
The strong correlations between Bpifb1 and Muc5b at the
mRNA and protein level were potentially suggestive of a
model in which the Chr 2 QTL leads to variation in Bpifp1
mRNA (i.e., is an eQTL), which in turn leads to variation in
MUC5B protein levels. However, neither Bpifb1 nor Muc5b
mRNAs were correlated with MUC5B protein levels in
BALF in pre-CC mice (Figure S9), ruling out the proposed
eQTL-based model. Rather, our data suggest an alternative
mechanism by which genetic variation in Bpifb1 affects
MUC5B, potentially through amino acid variants that af-
fect BPIFB1 protein structure/function. Musculus-derived
haplotypes (i.e., A/J, NOD/ShiLtJ, and PWK/PhJ) associ-
ated with low MUC5B levels share the alternative allele of
rs48926494, which encodes a valine to glycine substitution
at amino acid 23 of BPIFB1. As such, this SNP is a potential
causal variant.
Based on these results, we sought to further evaluate the
role of Bpifb1 using knockout (KO) mice. Using qRT-PCR, we
found that Bpifb1mRNAwas undetectable in KOmice (i.e., Ct
values $ 38). To confirm the loss of expression of BPIFB1
protein in KOmice, we sensitized and challengedWT and KO
mice with allergen to induce BPIFB1 protein expression and
Figure 1 MUC5AC and MUC5B
expression in CC founder strains.
Immunoblots for (A) MUC5AC
and (B) MUC5B in BALF of CC
founder strains sensitized and
challenged with Der p 1 (A/J chal-
lenged with PBS or Der p 1), with
n = 3–4 mice/strain. + denotes
BALF sample from a C57BL/6J
mouse treated with allergen in a
separate experiment and used as
positive control for antibody reac-
tivity. Quantification of protein
signal (integrated intensity a.u.)
for (C) MUC5AC and (D) MUC5B
show significant effect of strain
as calculated by ANOVA for
MUC5AC (P strain = 4.0 3 1027)
and MUC5B (P strain = 1.1 3
1025). Each circle represents one
mouse and the diamonds indicate
strain means.
did not detect any BPIFB1 protein by immunohistochemistry
in KO mice (Figure S10).
We then measured secreted MUC5B in Bpifb1WT and KO
mice at baseline and after Der p 1 allergen sensitization and
challengewith PBS or Der p 1 allergen (Figure 4A). Bpifb1 KO
mice had a threefold increase in MUC5B in BALF under
baseline conditions (“naïve”mice), which persisted after sen-
sitization with allergen and challenge with PBS. After sensi-
tization and allergen challenge, MUC5B in BALF increased
proportionally in both genotypes. Thus our results indicate
independent and additive effects for genotype and allergen
treatment (i.e., no genotype by treatment interaction).
MUC5AC was not affected by genotype in naïve or PBS-ex-
posed mice and did increase after allergen challenge as
expected, though the effect of genotype was not statistically
significant (Figure 4B). Results from histological analysis of
airway sections for luminal MUC5B content were consistent
with BALF MUC5B data (Figure 5). By quantitative morphom-
etry, there was a significant increase in the fraction of intra-
luminal AB-PAS positive material in Bpifb1 KO mice and a
matching trend for MUC5B (Figure 5C). Conversely, there
was a trend toward decreased MUC5B intracellular staining
in KO mice (Figure S11). These differences were present de-
spite roughly equal levels of airway inflammation as assessed
by differential bronchoalveolar lavage cell counts (Figure S12).
Discussion
We leveraged a series of genetic approaches, including an
inbred strain survey, QTLmapping, and functional analysis of
a candidate gene, to identify novel regulators of secreted
mucin levels in the airways. Our initial studies involving
theeightCC founder strainsdemonstrated thata large fraction
of thevariation in secretedMUC5ACandMUC5Bwasattribut-
able to genetic differences between strains. Having estab-
lished a genetic effect broadly, we turned to QTL mapping
in the pre-CC population to identify the specific genetic loci
that regulated these two secreted mucins. For the MUC5AC
QTL (Muc5acq1), we identified potential candidate genes
that merit exploration in future studies. Bpifb1 emerged as
a priority candidate gene for the MUC5B QTL (Muc5bq1)
based on a series of criteria, and we subsequently used Bpifb1
knockout mice to validate that BPIFB1 is causally related to
levels of MUC5B levels in the airways.
Our ability to identifyQTLand candidate geneswas greatly
facilitated by the use of the CC. In particular, the presence of
musculus-derived alleles in the CC was beneficial in at least
two ways. First, musculus-derived alleles were associated
with lower MUC5B compared to domesticus-derived alleles,
and because of the intersubspecific introgression (Yang et al.
2011) of musculus alleles into the genomes of the A/J and
Figure 2 QTL mapping for MUC5AC
and MUC5B expression and genetic
analysis of MUC5B QTL on Chr 2. Ge-
nome scans for (A) MUC5AC and (B)
MUC5B reveal distinct trans-pQTL. Note
that loci encoding Muc5ac and Muc5b
are located on chromosome 7. Dashed
line represents 95% significance thresh-
old determined by permutation. (C) Al-
lele effects plot of MUC5B. Each pre-CC
mouse is plotted by most probable CC
founder strain haplotype at Chr 2:154 Mb.
Differences between haplotype groupings
were determined using Tukey’s HSD test
indicated as # P = 0.06, * P , 1.0 3 1024.
(D) Phylogenetic tree of CC founder strains
for Chr 2:152,186,326–154,030,539 bp
reconstructed from sequence data shows
that there are three distinct alleles derived
from domesticus, castaneus, or musculus
(red branch) subspecies. Numbers indicate
bootstrap support estimates for each
branch (out of 100).
NOD/ShiLtJ founder strains, musculus-derived alleles were
present in.30% of pre-CCmice. Second, the intersubspecific
introgression of musculus alleles allowed us to narrow the
MUC5B QTL from 7.5 to ,2 Mb. In terms of quantitative
trait gene identification, these features complemented the
already enhanced mapping resolution (7.5–10 Mb) in the
CC compared to typical F2 intercrosses.
Whilewe detectedQTL for bothMUC5ACandMUC5B that
explain a relatively large fraction of phenotypic variance, our
data indicate that there are additionalQTL to identify. Indeed,
the broad-sense heritability estimates based on CC founder
strains were high, and the mucin phenotype distributions in
the pre-CC population were consistent with a polygenic basis
of inheritance. Future studies involving inbred CC strains,
with biological replicates, will facilitate the identification of
these additional loci. Study designs involving CC line inter-
crosses (recombinant inbred intercrosses)will also help explore
the possibility of epistasis between loci, which was potentially
suggested by the relatively large variance of MUC5B levels
among pre-CCmice with theM.m. musculus-derived haplotype
at the Chr 2 QTL.
The existence of distinct QTL for MUC5AC (Chr 13) and
MUC5B (Chr 2) indicates that these mucins are under the
control of distinct regulatory mechanisms in this model of
muco-obstructive airway disease. Additionally, we found that
while Muc5ac and Muc5b mRNA levels in the lung were
strongly correlated, ostensibly due to shared transcriptional
regulation, neither mRNA was correlated with the levels of
secreted MUC5AC or MUC5B. Thus, our results highlight the
existence of multiple regulatory pathways controlling the
levels of mucins in the airway that could be affected by genetic
variation. Given such complexity, it is perhaps not surprising
that we identified trans-pQTL for both mucins. Consequently,
we conclude that distal regulatory features separately control
the levels of these two mucins in the airway. These results con-
trast with what is typically observed for eQTL detected under
baseline conditions, which are often located close to genes, but
are consistent with a recent study showing that trans-pQTL are
abundant and often result from protein–protein interactions
(Chick et al. 2016). As such, we hypothesize that there may
be protein–protein interactions underlying the observed rela-
tionship between MUC5B and BPIFB1. In addition to the ob-
served strong correlation of MUC5B and BPIFB1 in the airways
of allergen-challenged mice, which is suggestive of protein
colocalization, BPIFB1 has been shown to have strong interac-
tions with mucins in human bronchial epithelial cell secretions
(Radicioni et al. 2016), supporting this hypothesis. Further-
more, we can rule out the possibility that variation in Bpifb1
gene expression underlies the QTL since Bpifb1mRNAwas not
correlated with secreted MUC5B.
Previous studies have provided evidence that BPIFB1 is
involved in human airway diseases in which MUC5B is upre-
gulated, including CF (Scheetz et al. 2004; Bingle et al. 2012)
and COPD (Gao et al. 2015; Titz et al. 2015), as well as IPF
(Yang et al. 2013; Gao et al. 2015). Data for the role of
BPIFB1 in asthma aremore sparse, but upregulation has been
observed in a study involving segmental allergen challenge
(Wu et al. 2005). There are conflicting reports of howMUC5B
levels change in asthma, with reports of increased MUC5B in
spontaneous sputum and asthmatic plugs (Groneberg et al.
2002; Kirkham et al. 2002) contrasting with a report of de-
creased MUC5B in induced sputum (Lachowicz-Scroggins
et al. 2016). A very recent report linked differences in the
glycosylation status of MUC5B to asthma exacerbations
Table 1 Meta-analysis of Muc5b and Bpifb1 gene expression in previous studies
Differential expression:
fold change vs. control
GEO ID Array platform Mouse strain Allergen Tissue ntreat/ncontrol Muc5b P-value Bpifb1 P-value
GSE1301a Affymetrix mouse
expression 430A array
Not reported HDM Whole lung 3/3 2.68 6.73E205 2.67 8.56E203
GSE13032b Affymetrix mouse
genome 430 2.0 array
A/J and
C57BL/6J
OVA Whole lung 3/3 A/J, 3/3
C57BL/6J




Not reported OVA Whole lung 3/3 1.48 6.87E202 1.61 3.61E202
GSE1438 Custom arrays BALB/c OVA Whole lung 5/5 1.55 2.50E201 1.60 1.10E201
GSE19223b Affymetrix mouse
exon 1.0 ST array
C57BL/6J and
BALB/cJ
HDM Whole lung 11/12 C57BL/6J,
11/14 BALB/cJ
2.21 7.45E203 3.77 2.11E203
GSE27066c Affymetrix mouse
genome 430 2.0 array
C57BL/6 OVA Whole lung 4/4 21.14 4.27E203 21.43 5.21E201
GSE34764 Affymetrix mouse
gene 1.0 ST array
C57BL/6 Alternaria Airway
epithelia
3/3 1.38 3.05E202 1.21 1.02E202
GSE6858 Affymetrix mouse
genome 430 2.0 array
BALB/cJ OVA Whole lung 4/4 3.89 5.74E204 2.67 9.64E203
Meta-analysis P-value 1.48E213 1.81E210
a Some studies included additional mice with engineered mutations which were not included in this meta-analysis.
b Analysis adjusted for strain.
c No upregulation of Muc5ac detected in this study.
(Welsh et al. 2017). We note that while some studies have
reported decreased MUC5B in asthma, antibody-based ap-
proaches may be biased due to protein degradation that
can occur in the context of inflamed or infected airways
(Henderson et al. 2014). This does not appear to have biased
our results, though, as we detected differences in MUC5B in
Bpifb1 KO mice compared to WT mice under baseline condi-
tions. However, quantification by mass spectrometry will be
necessary to measure the levels of MUC5B in a completely
unbiased manner. Nevertheless, the body of evidence that
MUC5B and BPIFB1 are upregulated in different airway dis-
eases suggests that the association between BPIFB1 and
MUC5B may be a common feature of obstructive lung dis-
eases in which MUC5B is elevated. Additionally, we showed
that this correlation is present at the level of gene expression
in multiple mouse models of asthma and at the protein level
upon allergen challenge.
Our data provide clear evidence that BPIFB1 is causally
related to MUC5B BALF levels. A rather simple hypothesis to
put forth is that BPIFB1 regulates some aspect (s) of MUC5B
accumulation in the airways. Indeed, we found evidence of an
increase in the fraction of AB-PAS positive luminal substance
in Bpifb1 KO mice whereas the total histological signal in the
airways was not affected by genotype. There are at least two
possible mechanisms that can explain our observations of
higher MUC5B levels in the Bpifb1 KO strain, namely en-
hanced secretion into the airways or reduced clearance from
the airways. Given that there is already evidence that BPIFB1
and MUC5B interact (Radicioni et al. 2016), it will be impor-
tant to investigate how these interactions affect secretion
and/or clearance in future studies. It is interesting to note
that in contrast to Bpifb1 KO mice, which had high MUC5B
levels, pre-CC mice with the musculus haplotype of Bpifb1
had lower levels of MUC5B. Thus, the putative causal variant
we identified (rs48926494) could impair secretion or facili-
tate clearance. The use of models that can produce either
high or low MUC5B in the airways as a function of Bpifb1
genotype will be an asset to the investigation of mucus
accumulation driven by the interactions between these
two proteins.
In summary, through our unbiased, genome-wide search,
we have identified distinct loci that regulate MUC5AC and
MUC5B levels in the airway after allergen sensitization and
challenge. We identified Bpifb1 as a candidate gene for the
MUC5B QTL, and confirmed a causal role for this gene in
regulating the levels of secreted MUC5B in the airways, a
phenotype that contributes to airway defense and multiple
airways diseases.
Figure 4 MUC5B expression increased in BALF
of Bpifb1 KO mice independent of treatment. (A)
MUC5B and (B) MUC5AC protein in BALF of naïve
mice and allergen-sensitized mice challenged with
PBS or Der p 1 for WT (light gray) or Bpifb1 KO (dark
gray) mice. Fold change of genotype for MUC5B:
3.2 (naïve), 2.7 (PBS), 1.8 (Der p 1); MUC5AC: 0.93
(naïve), 0.95 (PBS), 2.2 (Der p 1). n = 5 mice/genotype/
treatment. Mean 6 SEM depicted. Significance of
two-sided t-tests of genotype indicated as * P ,
0.05, ** P , 0.01, *** P , 0.001.
Figure 3 Correlated expression of MUC5B and BPIFB1 in airway ep-
ithelium. Der p 1 challenge elicits a correlated increase in MUC5B and
BPIFB1 in allergen-sensitized C57BL/6J mice. (A) Large airway staining
shows increase in AB-PAS, MUC5B, and BPIFB1 in airway epithelium.
Images representative of group based on average quantified signal.
Bar, 100 mM. (B) Quantitative morphometry of total airway signal (Vs,
mean 6 SEM) for PBS control (light gray) or Der p 1 treated (dark
gray) mice. n = 5–6 mice/treatment group. Fold change for treatment:
6.2 (AB-PAS), 5.4 (MUC5B), 4.5 (BPIFB1). Significance of two-sided
t-tests of treatment indicated as *** P , 0.001. (C) Correlation of
BPIFB1 and MUC5B total airway signal. Pearson’s correlation r = 0.98
(P , 0.001). Mice challenged with PBS (light gray) or Der p 1 (dark
gray).
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